Skip to search formSkip to main contentSkip to account menu

angelmarin

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
2016
2016
.................................................................................................................................. 4 INTRODUCTION.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 1. PANCREATIC CANCER. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 Statistics and Treatments for Pancreatic Cancer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 Pancreatic Cancer Cell. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 2. NATURAL PRODUCTS IN MEDICINE AND ANGELMARIN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Natural Products as Anticancer Agents. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Discovery of Angelmarin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 3. SAR STUDIES OF COUMARIN DERIVATIVES. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 SAR Study of Hydroxycoumarin Derivatives. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 SAR Study of Isoprenylated Coumarins. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 4. PREFERENTIAL CYTOTOXICITY OF COMPOUND 21. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Against Other Pancreatic Cancer Cell Lines. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Medium Component Study of Compound 21. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 5. INTRODUCTION TO INVESTIGATION. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 RESULTS AND DISCUSSION.................................................................................................. 24 1. PREPARATION OF COMPOUND 21. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 2. TIME DEPENDENT STUDY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 3. MEDIUM COMPONENT STUDY ON BxPC-3 AND COMPARISON. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28 New Reference Validation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28 Medium Component Study on BxPC-3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30 Comparison Among Three Pancreatic Cancer Cell Lines. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32 4. CYTO-ID KIT STUDY OF AUTOPHAGY IN PANC-1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34 Fluorescence Microscopy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34 Fluorescence Microplate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 5. WESTERN BLOTTING ANALYSIS OF AUTOPHAGY IN PANC-1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41 Effect of 21 and Autophagy Inhibitors on Conversion of LC3-I to II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41 Conversion of LC3-I to II Dependent on Time of Incubation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44 CONCLUSION........................................................................................................................... 46 METHODS AND MATERIALS................................................................................................ 47 1. PREPARATION OF COMPOUND 21. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47 2. TUMOR CELL CULTURE AND MEDIA PREPARATION. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48 3. CYTOTOXCITY ASSAYS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49 4. CYTO-ID AUTOPHAGY DETECTION KIT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51 5. WESTERN BLOTTING ANALYSIS OF AUTOPHAGY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52 REFERENCES ........................................................................................................................... 55 INDEX OF APPENDICES......................................................................................................... 57 
2015
2015
................................................................................................................................................ 5 INTRODUCTION ....................................................................................................................................... 6 NATURAL PRODUCTS IN MEDICINAL CHEMISTRY .................................................................................... 6 PANCREATIC CANCER ............................................................................................................................... 7 DISCOVERY AND SYNTHETIC HISTORY OF THE SPIROXINS ...................................................................... 9 MEDICINAL SIGNIFICANCE OF SPIROXIN A ............................................................................................ 12 SYNTHESIS OF THE CORE STRUCTURE OF SPIROXIN A ........................................................................... 13 STRUCTURE-ACTIVITY RELATIONSHIP (SAR) STUDY ........................................................................... 15 DISCOVERY OF ANGELMARIN ................................................................................................................. 16 NOVEL ISOPRENYLATED COUMARINS AND THEIR ANTITUMOR ACTIVITY ............................................ 16 INTRODUCTION TO INVESTIGATION ........................................................................................................ 19 1. Validation of Initial Lead Structure ............................................................................................... 19 2. SAR Study based on (S)-34 ............................................................................................................. 20 3. Effect of Medium Components on Cytotoxicity of 50 ..................................................................... 25 RESULTS AND DISCUSSION ............................................................................................................... 27 VALIDATION OF INITIAL LEAD STRUCTURE ........................................................................................... 27 SAR STUDY BASED ON (S)-34 ................................................................................................................ 28 1. Preparation of the SAR Library ..................................................................................................... 29 2. Biological Evaluations of SAR Analogs ......................................................................................... 39 EFFECT OF MEDIUM COMPONENTS ON CYTOTOXICITY OF 50 ............................................................... 44 FUTURE DIRECTIONS .............................................................................................................................. 48 CONCLUSION .......................................................................................................................................... 52 EXPERIMENTAL .................................................................................................................................... 53 GENERAL PROTOCOL .............................................................................................................................. 53 SYNTHESIS OF (R)-1,2-DIHYDRONAPHTHALEN-1-OL ((R)-33) ................................................................ 54 SYNTHESIS OF (R)-TERT-BUTYL((1,2-DIHYDRONAPHTHALEN-1-YL)OXY)DIPHENYLSILANE ((R)-34) ... 56 PREPARATION OF TERT-BUTYL((1,2-DIHYDRONAPHTHALEN-1-YL)OXY)DIPHENYLSILANE (34) ........... 57 SYNTHESIS OF TERT-BUTYLDIPHENYLSILANOL (55) ............................................................................... 58 SYNTHESIS OF (S)-1-(TRITYLOXY)-1,2-DIHYDRONAPHTHALENE ((S)-60) .............................................. 59 SYNTHESIS OF TERT-BUTYLDIMETHYLSILANOL (75) .............................................................................. 61 PREPARATION OF COMPLETE DULBECCO MODIFIED EAGLE’S MEDIUM (DMEM) ................................ 61 PREPARATION OF NUTRIENT-DEPRIVED MEDIUM, NUTRIENT-RICH MEDIUM AND MEDIA 1-6 ........... 62 TUMOR CELL CULTURE PROCEDURES .................................................................................................... 62 GENERAL PROCEDURES OF CYTOTOXICITY ASSAYS ............................................................................. 62 Cytotoxicity Assays of Spiroxin A Derivatives against PANC-1 ........................................................ 63 Cytotoxicity Assays of 50 against PANC-1 ........................................................................................ 63 Cytotoxicity Assays of 50 against BxPc-3 and Capan-2 .................................................................... 64 REFERENCES AND NOTES .................................................................................................................. 65 INDEX OF APPENDICES ....................................................................................................................... 68 
2012
2012
Inspired by nature: Angelmarin is an anticancer natural product with potent antiausterity activity, that is, selective… 
2009
2009
Angelmarin (1), a novel anti-cancer agent, was efficiently synthesized through a highly enantioselective epoxidation and a copper… 
Highly Cited
2006